CD28 and neuroblastoma: A Phase I trial with the 2G CE7 CAR in rotation with a similar third generation product that also includes a CD28 endodomain is currently underway at Seattle Children's Hospital for recurrent or refractory high risk neuroblastoma patients (NCT02311621).